Sivifene

Sivifene

SCHEMBL18821

O=[N+]([O-])c1ccc(NN=C(c2ccc(O)cc2)c2ccc(O)cc2)c([N+](=O)[O-])c1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.72
MEN1 O00255 5/20 0.72
MAPT P10636 12/20 0.56
MAPK1 P28482 8/20 0.56
TDP1 Q9NUW8 6/20 0.56
HTT P42858 4/20 0.56
L3MBTL1 Q9Y468 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
GAA P10253 5/20 0.54
POLB P06746 1/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 3/20 0.51
KDM4E B2RXH2 1/20 0.51
RECQL P46063 1/20 0.49
ALPI P09923 1/20 0.49
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sivifene SCHEMBL29386100 1.00 KMT2A (0.72) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL4109631 0.95 KMT2A (0.66) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL8591778 0.94 KMT2A (0.65) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL8591788 0.94 KMT2A (0.65) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL8591021 0.89 KMT2A (0.62) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL8594080 0.88 KMT2A (0.57) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL4132271 0.88 KMT2A (0.60) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL180084 0.87 KMT2A (0.72) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL180083 0.87 KMT2A (0.72) KMT2AMEN1MAPTMAPK1TDP1
SCHEMBL4132128 0.83 KMT2A (0.58) KMT2AMEN1MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2043 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346800-A1 REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR ENDORECHERCHE, INC. (CA) 2023-11-02 US claimed
US-11690852-B2 Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor ENDORECHERCHE. INC. 2023-07-04 US claimed
US-20220313703-A1 REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR ENDORECHERCHE, INC. (CA) 2022-10-06 US claimed
CN-109982701-B Application of SERD (serine-transferase) and CDK4/6 inhibitor and PI3K/mTOR pathway inhibitor 江苏恒瑞医药股份有限公司 2022-04-12 CN claimed
EP-2805945-B1 Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors MSD ITALIA SRL (IT) 2019-04-03 EP claimed
EP-3458015-A1 VAGINAL DELIVERY SYSTEMS CONTAINING SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF Azure Biotech, Inc. (US) 2019-03-27 EP claimed
US-20170333394-A1 VAGINAL DELIVERY SYSTEMS CONTAINING SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF Azure Biotech, Inc. 2017-11-23 US claimed
WO-2017201508-A1 VAGINAL DELIVERY SYSTEMS CONTAINING SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF Azure Biotech, Inc. (US) 2017-11-23 WO claimed
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. 2014-10-09 US claimed
US-8779171-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2014-07-15 US claimed
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2013-06-06 US claimed
US-20090247641-A1 HYDRAZONE AGENTS TO TREAT CUTANEOUS LESIONS DEKK-TEC, INC. 2009-10-01 US claimed
EP-1933824-A2 HYDRAZONE AGENTS TO TREAT CUTANEOUS LESIONS Dekk-Tec, Inc. (US) 2008-06-25 EP claimed
US-20070078114-A1 COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES MYRIAD GENETICS, INCORPORATED (US) 2007-04-05 US claimed
WO-2007025186-A2 HYDRAZONE AGENTS TO TREAT CUTANEOUS LESIONS DEKK-TEC, INC. (US) 2007-03-01 WO claimed
WO-1998058649-A1 SALT COMPLEX FOR LYMPHATIC DELIVERY DEKK-TEC, INC. (US) 1998-12-30 WO claimed
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-14 US disclosed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
WO-1998058649-A1 SALT COMPLEX FOR LYMPHATIC DELIVERY DEKK-TEC, INC. (US) 1998-12-30 WO disclosed
WO-1994005276-A1 CYTOTOXIC COMPOUNDS MORGAN LEE R (US) 1994-03-17 WO disclosed